Logo

Invitrogen Offers $300M in Convertible Notes to Repay Credit Line, Possibly Fund More M&A

Jun 14, 2005

NEW YORK, June 14 (GenomeWeb News) - Invitrogen said yesterday that it intends to offer $300 million of senior convertible notes due 2025.

 

Invitrogen said that purchasers of the notes will have an option to purchase up to an additional $50 million to cover over-allotments.

 

The company said it will use some of the net proceeds of the offering to repay around $124 million borrowed a revolving line of credit with Bank of America.

 

Invitrogen said it intends to use the balance of the net proceeds for "potential acquisitions and for general corporate purposes, including the potential repayment or redemption of other outstanding debt."

Breaking News
The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.